PALM BEACH GARDENS, Fla. & NEEDHAM, Mass.--(BUSINESS WIRE)--Xcovery, a developer of targeted therapeutics for cancer, today announced that Christine Lovly, MD, PhD, Assistant Professor of Medicine, Division of Hematology-Oncology at the Vanderbilt University School of Medicine will present a poster titled “Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)” at the American Association for Cancer Research (AACR) Annual Meeting 2016. The presentation details are as follows:
